GPN Vaccines to Highlight Serotype Independent Bacterial Vaccine Platform at Leading International Vaccines Congresses
Presentations will feature Gamma-PN clinical progress and early Gamma-SU findings supporting a broader approach to human and animal health NEW YORK, Sept. 28, 2026 /PRNewswire/ -- GPN Vaccines, Inc., a clinical-stage biotechnology company developing a new generation of broadly protective...